medium · CFA Level I ethics
Amberfen Pharma is being analyzed by a research analyst who attends a public industry conference. The analyst hears a supplier mention that Amberfen has significantly increased its orders for a specific raw material. Combining this with her own analysis of public clinical trial timelines, she issues a 'Strong Buy' rating. This is:
- A violation of Standard II(A) regarding material nonpublic information.
- Permissible under the mosaic theory.
- A violation of Standard I(C) Misrepresentation if the clinical trial outcomes are not yet guaranteed.
Sign up free to see the explanation and track your rank →
More CFA Level I ethics practice
- Which professional control is mandated for CFA candidates when using AI outputs?
- A trader at Helion Rail Securities receives a partial fill for a buy order of Vesper Foods
- Vesper Foods Investment Management has a policy to notify all clients of a 'Sell' rating v
- A manager at Meridian Pack receives an advance copy of a highly influential industry repor
- A trader at Vesper Foods learns from an internal IT error that the firm's quarterly revenu
- An advisor at Oakridge Capital is managing an account for his cousin. The cousin pays the
- A portfolio manager at Oakridge Capital wants to trade a stock for his personal account th
- According to Standard VI(B) Priority of Transactions, which statement best describes Julia